No Data
Yirui Biological (300942.SZ): Multiple pet infectious disease detection products have currently entered pet Hospitals.
On May 7, Gelonghui reported that Eryi Biological (300942.SZ) recently stated during an investor relations activity that the company has already launched various pet infectious disease testing products in pet Hospitals, meeting the need for rapid and accurate diagnosis of infectious diseases in pet Hospitals. The company is also continuously exploring new Business models, leveraging its outstanding R&D capabilities and high-quality product quality to establish deep cooperation with well-known animal protection companies, providing integrated services for product R&D and OEM. This cooperation model not only fully utilizes the company's core expertise in the development of testing reagents and production processes, but also opens up new Business growth points for the company, expanding its revenue.
Yiruisi Biotechnology (300942.SZ): The company currently has no business revenue from the USA.
On May 7, Gelonghui reported that Eryu Biology (300942.SZ) recently stated during an investor relations activity that there is currently no revenue from business activities in the USA, and the main raw materials produced by the company, including antigen antibodies and NC membranes, are not sourced from the USA. Self-manufacturing of antigen antibodies is an important reason for the company's high gross margin.
Shenzhen Bioeasy Biotechnology's (SZSE:300942) Solid Earnings May Rest On Weak Foundations
Yirui Biotech: 2024 Annual Report
Yirui Biotech: 2024 Annual Report Summary
Yirui Biotech: Report for the first quarter of 2025
Revenues Not Telling The Story For Shenzhen Bioeasy Biotechnology Co., Ltd. (SZSE:300942) After Shares Rise 27%
